RA Capital's disclosed 7.9M-share stake signals strong conviction in PRLD's pipeline. Given RA Capital's history of active engagement in biotech, watch for potential board representation or strategic catalysts. The recent insider buying cluster further supports bullish sentiment. Monitor for upcoming clinical data readouts or partnership announcements.
Price Chart
Executive Summary
RA Capital Healthcare Fund LP and related entities filed Form 3 initial beneficial ownership, disclosing a 7,882,882-share common stock position in Prelude Therapeutics Inc (PRLD). RA Capital is a prominent healthcare-focused investment firm; this filing formalizes a significant stake (~2.8% of shares outstanding based on market cap) and signals strong institutional interest in PRLD.
Key Facts
- RA Capital Healthcare Fund LP and related entities filed Form 3 initial statement of beneficial ownership
- Disclosed beneficial ownership of 7,882,882 shares of PRLD common stock
- Reporting owners include RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev Shah
- RA Capital is a well-known healthcare-focused investment firm with a track record of active engagement
- Recent insider buying of $15.5M over 30 days aligns with this institutional accumulation
Financial Impact
7,882,882 shares disclosed; based on $285M market cap and ~$28.5M stake value (assuming ~$3.62/share), this represents ~2.8% of outstanding shares
Risk Factors
- RA Capital may reduce position if pipeline milestones disappoint
- Biotech sector volatility could overshadow this positive signal
- No explicit timeline for catalyst disclosed in filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001231919-26-000420 |
| Document: 0001231919-26-000420-index.html | 0001231919-26-000420 |
| Document: 0001231919-26-000420.txt | 0001231919-26-000420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers